1. Home
  2. YSG vs TBPH Comparison

YSG vs TBPH Comparison

Compare YSG & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YSG

Yatsen Holding Limited

HOLD

Current Price

$4.09

Market Cap

889.0M

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$18.91

Market Cap

993.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YSG
TBPH
Founded
2016
2013
Country
China
United States
Employees
N/A
N/A
Industry
Package Goods/Cosmetics
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
889.0M
993.7M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
YSG
TBPH
Price
$4.09
$18.91
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$27.80
AVG Volume (30 Days)
238.0K
502.9K
Earning Date
02-24-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.58
Revenue
$571,300,568.00
$80,327,000.00
Revenue This Year
$28.96
$70.78
Revenue Next Year
$16.57
N/A
P/E Ratio
N/A
$31.54
Revenue Growth
22.59
27.12
52 Week Low
$3.01
$7.90
52 Week High
$11.57
$20.33

Technical Indicators

Market Signals
Indicator
YSG
TBPH
Relative Strength Index (RSI) 34.85 57.13
Support Level $3.88 $17.59
Resistance Level $4.45 $19.22
Average True Range (ATR) 0.22 0.62
MACD 0.07 -0.06
Stochastic Oscillator 33.08 81.50

Price Performance

Historical Comparison
YSG
TBPH

About YSG Yatsen Holding Limited

Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: